TSI’s manufacturing license for HMB approved in China

8b3549eb-fd9d-477a-a822-a79fbc3f5980articleimage.jpg

21 Aug 2017 --- TSI Group (TSI) has announced the approval of the first and only CFDA (China Food and Drug Administration) Manufacturing License for beta-hydroxy-beta-methylbutyrate (HMB) production in China. TSI’s Jiangyin Pharmaceutical facility, a wholly owned TSI Group company, received this exclusive license to produce HMB for use in Chinese food products.

Additionally, CFDA approved TSI’s HMB for an expanded range of Novel Food categories, such as beverages, chocolates, candies and baked goods. This approval is in addition to the existing and approved Chinese HMB markets; Sports Nutrition and Foods for Special Medical Purpose (FSMP, or Medical Foods).

“With the two new approvals, TSI is effectively positioned as the market leader and the only HMB manufacturer in China authorized to both produce and sell HMB ingredients domestically to the Chinese food and functional food markets and ultimately to deliver on our mission of promoting muscle health and to enhance consumers’ active lifestyles in China and around the world,” Alisan Sullivan, Senior Brand and Operations Manager, Innovative Products Division at TSI USA Inc., tells NutritionInsight.

TSI states that China is a key market for its global muscle health growth strategy and its mission is to deliver muscle health benefits that enhance and maintain consumers’ healthy and active lifestyles.

“After nearly two decades in the market and supported by a vast body of efficacy data (over 50 published clinical studies), HMB is a well-known and established staple for a sports enthusiast in the US and in Europe. With the sports nutrition market growing at 9 to 12 percent globally, and faster growth rates within the emerging economies like China, we see a great potential for our broad portfolio of HMB-based innovative and proprietary ingredients,” says Sullivan.

“Similarly, the general consumer awareness for HMB is growing fast, propelled by flagship products promoting muscle health and active lifestyle for elderly,” she adds.

“These recent regulatory approvals are significant milestones for all of us at TSI, the door is now wide open for us to deliver TSI’s world class HMB products to one of the fastest growing markets in the world – China,” concludes Larry Kolb, President, TSI Group. “We know HMB can make a difference in people’s daily lives and are excited for the opportunity to positively impact muscle health for millions of Chinese consumers – from athletes of all kinds to aging adults.”

By Paul Creasy

Related Articles

Nutrition & Health News

“Unhelpful”: EU regulatory framework fuels nutrition industry dissatisfaction 

16 Feb 2018 --- A survey reveals that one-third of all nutrition industry professionals believe that the current EU framework for achieving a health claim on new products is stunting innovation because it’s complicated, expensive, long-winded and has several “gray areas.” And “regulation frustration” is a strong feeling running through the industry with many more professionals now believing the current EU regulatory environment is “unhelpful” – a 25 percent hike compared with statistics from the beginning of 2017. Experts are attributing this sharp rise in dissatisfaction to the EU’s tough stance on health claims and the current regulatory deadlock on botanicals.

Nutrition & Health News

Research driving demand for OPO in China’s formula market: Advanced Lipids

16 Feb 2018 --- OPO is increasing in popularity in China’s infant formula market, and according to Advanced Lipids, this is down to the growing body of scientific research backing the benefits of this ingredient. Also known as SN-2 palmitate, OPO is a premium quality ingredient that mimics the fatty acid profile of human milk.

Nutrition & Health News

EID Parry and Synthite Industries partner on phycocyanin production 

08 Feb 2018 --- Enhanced health company Valensa International has entered into a joint venture agreement between Valensa’s parent company EID Parry and Synthite Industries Ltd, which promises to boost microalgae extracts for nutraceutical applications. It involves a US$6.5 million investment in an India-based manufacturing facility for the extraction of Parry Organic Spirulina to produce Phycocyanin, which Valensa will be developing for dietary supplements, functional and medical foods.

Nutrition & Health News

L-Carnitine – "Unquestionable" room for market growth: Lonza

08 Feb 2018 --- From facilitating the recovery process in the sports nutrition sector to improving energy metabolism in healthy aging products, L-Carnitine has proven itself a versatile ingredient with the potential to be applied in myriad applications. “Sports nutrition, weight management, all these areas are still growing. There is no question that there is a lot of room for L-Carnitine’s development. We see a lot of demand coming from Asia and Africa for infant food applications. The other big market is for sure energy drinks,” Marco Gossen, Business Development Manager at Lonza, explains during a NutritionInsight webinar last week, looking at product development and untapped opportunities for L-Carnitine.

Nutrition & Health News

Immunity boosters (Part 1): Not diplomatic about immunity – Trends, opportunities and delivery systems

06 Feb 2018 --- Immunity boosters are a popular way of staying on top of immune health: from capsules and tablets to fortified food and beverages, these ingredients are in demand all year round thanks to their protective qualities. Today, NutritionInsight takes a look at the latest developments on the immunity platform.

More Articles
URL : http://www.nutritioninsight.com:80/news/tsis-manufacturing-license-for-hmb-approved-in-china.html